Italian diffuse/multivessel disease Absorb prospective registry (IT-DISAPPEARS). Study design and rationale

Journal of Cardiovascular Medicine

Volumn 16, Issue 3, 2015, Pages 253-258

  Testa, Luca ^a   Zoccai, Giuseppe Biondi ^b   Tomai, Fabrizio ^c   Ribichini, Flavio ^d   Indolfi, Ciro ^e   Tamburino, Corrado ^f   Bartorelli, Antonio ^a   Petronio, Anna Sonia ^h   Bedogni, Francesco ^g   De Carlo, Marco ^h  

^a Istituto Clinico S Ambrogio   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c EUROPEAN HOSPITAL   (Italy)

^d UNIVERSITY OF VERONA   (Italy)

^e UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^f Ferrarotto Hospital   (Italy)

^g CENTRO CARDIOLOGICO MONZINO   (Italy)

^h UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; EVEROLIMUS;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; BIORESORBABLE SCAFFOLD; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; ITALY; MAJOR CLINICAL STUDY; PATIENT SAFETY; STUDY DESIGN; BIODEGRADABLE IMPLANT; DEVICES; DRUG ELUTING STENT; METHODOLOGY; PERCUTANEOUS CORONARY INTERVENTION; REGISTER; TISSUE SCAFFOLD;

ABSORBABLE IMPLANTS; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; HUMANS; PERCUTANEOUS CORONARY INTERVENTION; REGISTRIES; RESEARCH DESIGN; TISSUE SCAFFOLDS;

EID: 84925851874     PISSN: 15582027     EISSN: 15582035     Source Type: Journal    
DOI: 10.2459/JCM.0000000000000219     Document Type: Article

References (31)

1. Sigwart U, Puel J, Mirkovitch V, et al. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 1987;316:701-706.
2. Gruntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med 1979;301:61-68.
3. De Feyter PJ, De Jaegere PP, Serruys PW. Incidence, predictors, and management of acute coronary occlusion after coronary angioplasty. Am Heart J 1994;127:643-651.
4. Serruys PW, De Jaegere P, Kiemeneij F, et al., for the Benestent Study Group. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994;331:489-495.
5. Fischman DL, Leon MB, Baim DS, et al., for the Stent Restenosis Study Investigators. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994;331:496-501.
6. Barragan P, Sainsous J, Silvestri M, et al. Ticlopidine and subcutaneous heparin as an alternative regimen following coronary stenting. Catheter Cardiovasc Diagn 1994;32:133-138.
7. Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronaryartery stents. N Engl J Med 1996;334:1084-1098.
8. Cutlip DE, Leon MB, Ho KK, et al. Acute and nine-month clinical outcomes after 'suboptimal' coronary stenting: results from the STent Antithrombotic Regimen Study (STARS) registry. J Am Coll Cardiol 1999;34:698-706.
9. Colombo A, Hall P, Nakamura S, et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation 1995;91:1676-1688.
10. Serruys PW, Kutryk MJ, Ong AT. Coronary-artery stents. N Engl J Med 2006;354:483-495.
11. Karas SP, Gravanis MB, Santoian EC, et al. Coronary intimal proliferation after balloon injury and stenting in swine: an animal model of restenosis. J Am Coll Cardiol 1992;20:467-474.
12. Gordon PC, Gibson CM, Cohen DJ, et al. Mechanisms of restenosis and redilation within coronary stents: quantitative angiographic assessment. J Am Coll Cardiol 1993;21:1166-1174.
13. Hoffmann R, Mintz GS, Dussaillant GR, et al. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation 1996;94:1247-1254.
14. Moliterno DJ. Healing Achilles: sirolimus versus paclitaxel. N Engl J Med 2005;353:724-727.
15. Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drugeluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007;370:937-948.
16. Spaulding C, Daemen J, Boersma E, et al. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007;356:989-997.
17. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimusand paclitaxel-eluting coronary stents. N Engl J Med 2007;356:998-1008.
18. Mauri L, Hsieh WH, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007;356:1020-1029.
19. Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimuseluting stents with bare-metal stents. N Engl J Med 2007;356:1030-1039.
20. Jeremias A, Kirtane A. Balancing efficacy and safety of drug-eluting stents in patients undergoing percutaneous coronary intervention. Ann Intern Med 2008;148:234-238.
21. Ormiston JA, Serruys PW, Regar E, et al. A bioabsorbable everolimuseluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet 2008;371:899-907.
22. Serruys PW, Onuma Y, Ormiston JA, et al. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation 2010;122:2301-2312.
23. Ribichini F, Romano M, Rosiello R, et al., EXECUTIVE Trial Investigators. A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease: the EXECUTIVE trial (EXecutive RCT: evaluating XIENCE V in a multi vessel disease). JACC Cardiovasc Interv 2013;6:1012-1022.
24. Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012;33:2569-2619.
25. Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32:2999-3054.
26. Wijns W, Kolh P, Danchin N, et al. Guidelines on myocardial revascularization. Eur Heart J 2010;31:2501-2555.
27. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115:2344-2351.
28. Farooq V, Gogas BD, Serruys PW. Restenosis: delineating the numerous causes of drug-eluting stent restenosis. Circ Cardiovasc Interv 2011;4:195-205.
29. Baber U, Mehran R, Sharma SK, et al. Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials. J Am Coll Cardiol 2011;58:1569-1577.
30. McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004;364:1519-1521.
31. Stefanini GG, Kalesan B, Serruys PW, et al. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS):4 year follow-up of a randomised noninferiority trial. Lancet 2011;378:1940-1948.